AbstractThis feature layer describes the location of Australia’s public hospitals, operational at some point during the 2022-23 Financial Year. A public hospital is defined as a hospital included in the Australian Institute of Health and Welfare’s (AIHW) National Public Hospital Establishment (NPHE) database, for the relevant financial year.The NPHE database holds data for each public hospital in Australia, including public acute hospitals, psychiatric hospitals, drug and alcohol hospitals and dental hospitals in all states and territories. Hence, public hospitals not administered by the state and territory health authorities (hospitals operated by correctional authorities for example, and hospitals in offshore territories) are not included.For this feature layer, an NPHE hospital is only included if it was also included in the AIHW’s count of public hospitals as reported in the online Hospital Resources data tables for the relevant financial year (2022-23: https://www.aihw.gov.au/getmedia/06f2c08c-f00f-439e-b57c-9a825ffc505c/Hospital-resources-tables-2022-23.xlsx).As noted in the AIHW’s technical appendix accompanying the NPHE data, the number of public hospitals reported can be affected by administrative and/or reporting arrangements and is not necessarily a measure of the number of physical hospital buildings or campuses. For more information on the 2022-23 NPHE see: https://www.aihw.gov.au/getmedia/747ae239-e38b-45a9-8d83-0ac6a3e0726f/hospital-resources-2022-23-appendix.pdfThe original data source for the public hospital layer is not the same as the Commonwealth’s list of declared hospitals (https://www.health.gov.au/resources/publications/list-of-declared-hospitals), however, there is considerable cross-over between the NPHE and Commonwealth list. There are a small number of private hospitals in the Commonwealth list of hospitals that are treated as public hospitals by the AIHW in NPHE. For 2022-23, these hospitals are:Hawkesbury District Health Service (NSW)Northern Beaches Hospital (NSW)Mclaren Vale & Districts War Memorial Hospital Incoperated (SA)Joondalup Health Campus (WA)St John Of God Midland Public & Private Hospital (WA)CurrencyDate modified: September 2024Modification frequency: As neededData ExtentSpatial ExtentWest: 96.82°South: -43.74°East: 167.99°North: -9.14°Source InformationAustralian Institute of Health and Welfare’s (AIHW) National Public Hospital Establishment (NPHE) databaseAustralian Department of Health, Disability and Ageing: Geospatial Data HubLineage StatementA public hospital is defined as a hospital included in the Australian Institute of Health and Welfare’s (AIHW) National Public Hospital Establishment (NPHE) database, for the relevant financial year.Data DictionaryAttribute NameDescriptionOBJECTIDAutomatically Generated System IDhsib_idDepartment of Health, Disability and Ageing unique identifier for each hospitalhosp_nameHospital NamecategoryHospital typestreetStreetpcodePost CodesuburbSuburbstateState/TerritoryxcoordLongitudeycoordLatitudeContactContact: Department of Health, Disability and Ageing, geospatial@health.gov.au

The Australian Burden of DiseaseDatabase contains aggregated output of burden of disease metrics from the Australian Burden of Disease Study. This includes Years of life lost (YLL), Years lived with disability (YLD) and Disability adjusted life years (DALY) for around 200 diseases and injuries. It also includes estimates of attributable burden (DALY) for around 30 risk factors.

The Australian Burdenof Disease Database was established as part of the Australian Burden of Disease Study 2011 to set up the relevant infrastructure to enable efficient and timely ongoing updates by the AIHW as required. The database is updated and added to following the completion of each ABDS. It currently includes national estimates of disease burden and risk factor attribution for 2003, 2011, 2015, 2018. Projected estimates of disease burden are also available for 2022 and 2023. Subnational estimates of disease burden are available for state/territory, remoteness, and socioeconomic group for 2011, 2015 and 2018. Subnational estimates of risk factor attribution are available for socioeconomic group for 2015 and 2018. Indigenous-specific estimates of disease burden and risk factor attribution are available for 2003, 2011 and 2018. All data are available by 5- year age group and sex.

Australia Continuous Glucose Monitoring Devices Market size was valued at USD 140.51 Million in 2024 and is projected to reach USD 360.53 Million by 2032, growing at a CAGR of 12.5% from 2026 to 2032.Key Market DriversRising Diabetes Prevalence: The increasing incidence of both Type 1 and Type 2 diabetes in Australia creates a direct expansion of the potential user base for CGM devices. This growth is driven by factors including an aging population, lifestyle changes, and improved diagnosis rates. According to the Australian Institute of Health and Welfare, approximately 1.3 million Australians will be living with diabetes in 2022. The National Diabetes Services Scheme diabetes prevalence increased by 4.3% annually between 2020-2022. Government Subsidy Programs: Australian government initiatives provide financial support for CGM devices through various healthcare programs, making these devices more accessible to eligible patients, particularly children and young adults with Type 1 diabetes. The Australian Government expanded the CGM Initiative in July 2022, investing AUD 273.1 million over four years to provide free CGM devices to all people with Type 1 diabetes.

This is the 14th in a series of surveys auspices by the National Drug Strategy (and its predecessors) and the 9th to be conducted by the AIHW. It is a national household survey of non-institutionalised persons aged 14 years and over. There were 21,663 completed responses in 2022-2023. Fieldwork was conducted by Roy Morgan Research.

Private dwellings from people aged 14 years or older. Excluded from sampling were non private dwellings (hotels, motels, boarding houses, etc.) and institutional settings (hospitals, nursing homes, other clinical settings such as drug and alcohol rehabilitation centres, prisons, military establishments and university halls of residence). Persons who were homeless were also excluded as well as the territories of Jervis Bay, Christmas Island and Cocos Island.

This data relates to trends in and causes of vaping behaviors in Australian teenagers. Data has been taken from the Australian Institute of Health and Welfare and the Cancer Council. Australian Institute of Health and Welfare (2024). Data tables: National Drug Strategy Household Survey 2022–2023 – 3: Electronic cigarettes and vapes. https://www.aihw.gov.au/getmedia/da885ce8-2936-48d3-a3f7-69e19376289a/aihw-phe-340-National-Drug-Strategy-Household-Survey-2022-2023-2-Tobacco-smoking.xlsxScully, M., Bain, E., Koh, I., Wakefield, M., & Durkin, S. (2023). ASSAD 2022-2023: Australian secondary school students’ use of tobacco and e-cigarettes. Cancer Council Victoria. https://www.health.gov.au/sites/default/files/2024-04/australian-secondary-school-students-use-of-tobacco-and-e-cigarettes-2022-2023.pdf

Australia Life And Non-Life Insurance Market size was valued at USD 49.14 Billion in 2024 and is projected to reach USD 70.20 Billion by 2032, growing at a CAGR of 4.56% from 2026 to 2032.

Australia Life And Non-Life Insurance Market Dynamics

The key market dynamics that are shaping the Australia life and non-life insurance market include:

Key Market Drivers

Aging Population: Australia's population is rapidly aging, with forecasts predicting that by 2041, almost 22% of Australians would be 65 or older (Australian Institute of Health and Welfare, 2023). As older people seek financial stability, there is a surge in demand for life insurance and retirement planning services.

Increasing Awareness of Health Risks: As the prevalence of lifestyle-related health conditions rises, people are looking for comprehensive health and life insurance. According to the Australian Institute of Health and Welfare, more than 67% of Australian adults are overweight or obese (2022)

The Global Acute Respiratory Distress Syndrome Treatment market size was USD 2948.8 Million in 2022. Acute Respiratory Distress Syndrome Treatment Industry's Compound Annual Growth Rate will be 5.90% from 2023 to 2030. What are the Prime Drivers Influencing the Growth of the Acute Respiratory Distress Syndrome Treatment Market?

Rising Need for ARDS Treatment to Provide Viable Market Output

The demand for ARDS treatment arises from an uptick in hospital and critical care unit admissions, driving the market's growth. According to a study titled "Acute respiratory distress syndrome readmissions: A countrywide cross-sectional analysis of epidemiology and costs of care in January 2022, 18.4% of patients with acute respiratory distress syndrome required re-hospitalization. Moreover, data from the Australian Institute of Health and Welfare, published in May 2022, reveals 11.8 million hospital admissions in 2020–21, marking a 6.3% increase from 2019–20. Among these admissions, 7.0% involved an ICU stay, 3.8% were related to respiratory disease, and 10.3% resulted in the patient passing away in the hospital.

On May 10, 2021, Medtronic plc, a worldwide leader in medical technology, declared the official introduction of their SonarMed airway monitoring system in the United States. This innovative device, which is unparalleled in its field, employs acoustic technology to immediately detect potential blockages and ensure the correct positioning of endotracheal tubes (ETT). By providing real-time data, the SonarMed airway monitoring system equips healthcare professionals with crucial information necessary to make well-informed, life-saving judgments when caring for their tiniest patients

The Key Factors that Hinder the Growth of the Acute Respiratory Distress Syndrome Treatment Market

Increasing Cost of Treatment Therapeuticsto Hinder Market Growth

Several factors drive the cost of treatment rectifiers in the ARDS treatment request; developing new treatments for ARDS is a complex and precious process. It can take numerous times and millions of bones to bring a new treatment to market. Limited vacuity of payment in numerous countries, there's limited payment for ARDS treatments. This can make it difficult for cases to pierce the care they need. The cost of hospitalization for ARDS can be high due to the need for ferocious care and other technical services. There are presently no general druthers to the most effective treatments for ARDS. This means that cases have to pay the full price for these treatments. The added cost of treatment rectifiers is a major challenge for the ARDS treatment request. It can make it delicate for cases to pierce the care they need and limit the development of new treatments.

Impact Of COVID-19 on the Acute Respiratory Distress Syndrome Treatment Market

The ARDS treatment market has been greatly affected by the COVID-19 pandemic. The virus can induce a severe and potentially lethal condition called acute respiratory distress syndrome (ARDS), which predominantly targets the lungs. Consequently, there has been a notable increase in the occurrences of ARDS among individuals infected with COVID-19. This has led to a substantial increase in the demand for ARDS treatments, including mechanical ventilation and ECMO. Furthermore, the pandemic has spurred intensified research and development activities to discover new treatment options for ARDS. Consequently, the ARDS treatment market is expected to experience substantial growth in the coming years. The increased demand for ARDS treatments is primarily driven by the rising number of individuals diagnosed with ARDS due to COVID-19. In summary, the COVID-19 pandemic has profoundly impacted the ARDS treatment market, which is anticipated to expand significantly in the coming years due to the growing number of ARDS cases and advancements in treatment research. Introduction of Acute Respiratory Distress Syndrome Treatment

ARDS is a medical condition where the lungs cannot effectively absorb enough oxygen and provide it to essential organs. This happens because fluid builds up in the alveoli, which hinders the lungs from fully filling with air, resulting in less oxygen reaching the bloodstream. The global market for treating acute respiratory distress syndrome has experienced significant growth due to increased investments in research by both government and private organizations.

These developmen...